|
1
|
Rial M Botana, Fernández-Villar A,
González Piñeiro A and Leiro Fernandez V: Primary lung
adenocarcinoma with ovarian metastasis: A rare presentation of
bronchogenic carcinoma. Arch Bronconeumol. 45:571–572. 2009.(In
Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Islami F, Torre LA and Jemal A: Global
trends of lung cancer mortality and smoking prevalence. Transl Lung
Cancer Res. 4:327–338. 2015.PubMed/NCBI
|
|
3
|
Irving JA and RH Y: Lung carcinoma
metastatic to the ovary: A clinicopathologic study of 32 cases
emphasizing their morphologic spectrum and problems in differential
diagnosis. Am J Surg Pathol. 29:997–1006. 2005.PubMed/NCBI
|
|
4
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, et al: Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature. 448:561–566.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Young RH and Scully RE: Ovarian metastases
from cancer of the lung: Problems in interpretation - a report of
seven cases. Gynecol Oncol. 21:337–350. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vang R and Ronnett BM: Metastatic and
miscellaneous primary tumors of the ovaryGynecologic Pathology.
Nucci MR and Oliva E: Elsevier Churchill Livingstone; Philadelphia:
pp. 539–614. 2009, View Article : Google Scholar
|
|
7
|
Kim K, Cho SY, Park SI, Kang HJ, Kim BJ,
Kim MH, Choi SC, Ryu SY and Lee ED: Risk of metastatic ovarian
involvement in nongynecologic malignancies. Int J Gynecol Cancer.
22:3–8. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shi Y, Ye D, Lu W, Zhao C, Xu J and Chen
L: Histological classification in 10 288 cases of ovarian malignant
tumors in China. Zhonghua Fu Chan Ke Za Zhi. 37:97–100. 2002.(In
Chinese). PubMed/NCBI
|
|
9
|
American Joint Committee on Cancer, . Lung
Cancer Staging. 7th edition. http://cancerstaging.org/references-tools/quickreferences/documents/lungmedium.pdfAccessed
March 7, 2015.
|
|
10
|
Yeh KY, Chang JW, Hsueh S, Chang TC and
Lin MC: Ovarian metastasis originating from bronchioloalveolar
carcinoma: A rare presentation of lung cancer. Jpn J Clin Oncol.
33:404–407. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ordóñez NG: Thyroid transcription factor-1
is a marker of lung and thyroid carcinomas. Adv Anat Pathol.
7:123–127. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Suzuki A, Shijubo N, Yamada G, Ichimiya S,
Satoh M, Abe S and Sato N: Napsin A is useful to distinguish
primary lung adenocarcinoma from adenocarcinomas of other organs.
Pathol Res Pract. 201:579–586. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bishop JA, Sharma R and Illei PB: Napsin A
and thyroid transcription factor-1 expression in carcinomas of the
lung, breast, pancreas, colon, kidney, thyroid, and malignant
mesothelioma. Hum Pathol. 41:20–25. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Soria JC, Mok TS, Cappuzzo F and Jänne PA:
EGFR-mutated oncogene-addicted non-small cell lung cancer: Current
trends and future prospects. Cancer Treat Rev. 38:416–430. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shaw AT, Yeap BY, Mino-Kenudson M,
Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S,
McDermott U, et al: Clinical features and outcome of patients with
non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol.
27:4247–4253. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Solomon B, Varella-Garcia M and Camidge
DR: ALK gene rearrangements: A new therapeutic target in a
molecularly defined subset of non-small cell lung cancer. J Thorac
Oncol. 4:1450–1454. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mano H: Non-solid oncogenes in solid
tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci.
99:2349–2355. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Horn L and Pao W: EML4-ALK: Honing in on a
new target in non-small-cell lung cancer. J Clin Oncol.
27:4232–4235. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takahashi T, Sonobe M, Kobayashi M,
Yoshizawa A, Menju T, Nakayama E, Mino N, Iwakiri S, Sato K,
Miyahara R, et al: Clinicopathologic features of non-small-cell
lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 17:889–897.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
XALKORI®: (crizotinib) (package
insert). Pfizer, NY: 2012, http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202570s002lbl.pdf
|
|
21
|
Kwak EL, Bang YJ, Camidge DR, Shaw AT,
Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, et al:
Anaplastic lymphoma kinase inhibition in non-small-cell lung
cancer. N Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fujiwara A, Higashiyama M, Kanou T,
Tokunaga T, Okami J, Kodama K, Nishino K, Tomita Y and Okamoto I:
Bilateral ovarian metastasis of non-small cell lung cancer with ALK
rearrangement. Lung Cancer. 83:302–304. 2014. View Article : Google Scholar : PubMed/NCBI
|
